Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses
  • Ocular DB

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

The clinical evaluation of drugs for leprosy

Browne S. Oxford University Press (OUP). Transactions of the Royal Society of Tropical Medicine and Hygiene. 1967; 61 (4) : 601-607.
Publication

Lepra – in Europa unbekannt und in der Welt vergessen

Maurer ME, Deußing M, Sattler EC, et al. Springer Science and Business Media LLC. Die Dermatologie. 2024; 75 (S1) : 20-24.
Download PDF
Publication

Comparison between histopathologic features of leprosy in reaction lesions in HIV coinfected and non-coinfected patients

Pires CAA, Miranda MFRD, Bittencourt MDJS, et al. FapUNIFESP (SciELO). Anais Brasileiros de Dermatologia. 2015; 90 (1) : 27-34.
Download PDF
Publication

The Treatment of Leprosy by Intravenous Injections of Iodoform.

Courtney B. Elsevier BV. The Lancet. 1914; 183 (4739) : 1806-1808.
Download PDF
Publication

Healing of leprosy-associated chronic plantar wounds with a novel biomembrane containing latex proteins from Calotropis procera

Nunes MO, Alencar NMN, Pontes MAA, et al. FapUNIFESP (SciELO). Brazilian Journal of Biology. 2024;
Download PDF
Publication

A rare case of pure neuritic leprosy with hereditary spherocytosis: implications for dapsone use

Agrawal S, Borkar M, Deoke S. Leprosy Review. 2024;
Download PDF
Publication

Dapsone-induced haemolysis among leprosy patients on MDT from an endemic area of central India

Naik KP, Ganguly S, Shukla AK, et al. Medknow. Journal of Family Medicine and Primary Care. 2024; 13 (9) : 3887-3891.
Download PDF
Publication

Pure neuritic leprosy: Latest advancements and diagnostic modalities

Razdan N, V B, Sadhu S. Elsevier BV. Diagnostic Microbiology and Infectious Disease. 2024; 110 (4) : 116-529.
Publication

Case Report: Leprosy Masquerading as Relapsing Polychondritis

Goel R, Rashmi R, Ghosh D, et al. American College of Rheumatology. 2024;
Download PDF
Publication

Frequency of depressive symptoms in patients with leprosy from a city in the Colombian Caribbean

Romero SS, Perez PB, Herrera Y, et al. Risaralda Medical Journal. 2023;
Download PDF

Pagination

  • Previous page ‹‹
  • Page 62
  • Next page ››
Subscribe to Leprosy (Hansen disease)

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

© 2025 InfoNTD